Skip to main content

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca AB

Start Date

July 27, 2018

End Date

July 15, 2023
 

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca AB

Start Date

July 27, 2018

End Date

July 15, 2023